



ABN 82 010 975 612

Level 18, 101 Collins Street
Victoria 3000 Australia
Telephone: + 61 7 3273 9133
Facsimile: + 61 7 3375 1168
www.tbgbio.com

TBG Diagnostics Received ASHI accreditation for Xiamen facility

Key highlights

- **American Society for Histocompatibility and Immunogenetics (ASHI) is globally recognised accreditation standard of highest order**
- **ASHI is specific to transplant laboratories and the reports can be accepted internationally**
- **TBG now has two ASHI accredited laboratories; Taiwan and Xiamen, China**

Melbourne, Australia, 19 May 2017. The Board of TBG Diagnostics Limited (ASX: TDL, OTC: PGLA) (the **Company** or **TBG**) is pleased to announce that its Xiamen laboratory has been accredited by the international recognised authority, American Society for Histocompatibility and Immunogenetics (ASHI). The accreditation ensures that the Xiamen facility produces results that are of a recognised high-quality standard. The accreditation comes at the completion of a program that evaluates a number of important requirements for the HLA laboratory, including; personnel, procedures, facility presentation and clinical services.

This accreditation supports TBG in its endeavours to be the leading supplier of HLA products and services within the Asian region. The Xiamen and Taiwan facilities provide TBG with excellent portals to achieve the company vision.

TBG Diagnostics' Xiamen laboratory is a state-of-the-art facility, newly built and operating in the city of Xiamen, in the Fujian province of China. Xiamen is recognised as a one of China's five special economic development zones and therefore represents a key industry area to showcase Chinese technology. The TBG facility commenced HLA Typing in Xiamen in July 2016 and continues to build on its core technologies of IVD-related nucleic acid testing kits, to include infectious diseases, oncology, blood screening and genetic testing. TBG intends to supply products and services into the growing Chinese Molecular Diagnostics (MDx) market that is expected to grow to \$3.46 billion USD by 2024.

Chief Executive Officer of TBG Biotechnology Taiwan Chief Operating Officer, Eugene Cheng said:
"While it is an honour to receive the ASHI accreditation to our Xiamen laboratory, it has from the outset, been the aim of TBG to achieve the highest operating recognition for our company wherever it operates. It is the aim of TBG to be the leading supplier of the highest quality HLA and In Vitro Diagnostics products into China and the Asian region. I thank all our team at TBG Xiamen and TBG Taiwan for their efforts in this achievement."

Investor Relations and Media Contact:

Peter Taylor
NWR Communications
+61 412 036 231
peter@nwrcommunications.com.au

About TBG Diagnostics

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. TBG is focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services

TBG Diagnostics is an established brand with a strong presence in the Asian market. From its plant in Xiamen, China it develops and manufactures:

- Nucleic Acid Test (NAT) products
- HLA typing reagents based on NAT technologies
- Automation systems for NAT operations
- IVD-related NAT kits and services

Products distributed to more than 22 countries. Major hospital and laboratory clients in USA, Taiwan, Germany, Portugal, China, Hong Kong and Singapore. Operating in the rapidly growing IVD market - US\$53 billion in 2013 and expected to reach US\$74.7 billion by 2020. Targeting further growth in China - fastest growing MDx market at CAGR of 27.9%. Extensive research and development pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases

About ASHI

The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum of exchange of information and advocating the highest standards of laboratory testing in the interest of optimal patient care.

<http://www.ashi-hla.org/>